The invention relates generally to medical devices and more specifically to methods of plating and soldering together portions of medical devices.
Medical devices such as distal protection filters and guidewires can include portions that are made from a variety of different metals. Some of these metals, such as stainless steel and nickel/titanium alloys, are readily oxidized when exposed to air. It has been found that a surface layer of oxidized metal can interfere with soldering processes.
Thus, a need remains for an improved method of soldering oxidizable metals such as stainless steel and nitinol.
The present invention is directed to an improved method of plating oxidizable materials. Once plated, such materials can be soldered using conventional solders and fluxes. Medical devices can be assembled by soldering together plated materials. Oxidizable materials can be plated with radiopaque materials to yield medical devices that are more visible to fluoroscopy.
Accordingly, an embodiment of the present invention can be found in a method of plating a medical device that includes an oxidizable substrate. The substrate can be cleaned with a cleaning and etching solution, and can be activated with a concentrated aqueous solution of ammonium bifluoride. A rinsing step ensues in which the substrate can be rinsed with a dilute aqueous solution of ammonium bifluoride. The substrate can be plated with a plating material.
Another embodiment of the present invention is found in a method of forming a medical device that has a first metal part and a second metal part. The first metal part is made of an oxidizable metal. The first metal part can be cleaned with a cleaning and etching solution and can then be activated with a concentrated aqueous solution of ammonium bifluoride. The first metal part can be rinsed with a dilute aqueous solution of ammonium bifluoride and can be electroplated. Finally, the plated first metal part can be soldered to the second metal part. In a particular embodiment, the second metal part is also treated as described above, prior to soldering.
An embodiment of the present invention is found in a method of forming a filter wire loop from a nitinol filter wire that is secured at either end to a stainless steel wire. Both ends of the nitinol wire can be cleaned with a cleaning and etching solution and can then be activated with an aqueous solution that includes about 10 to 40 weight percent ammonium bifluoride. The ends of the wire can be rinsed with an aqueous solution that includes about 1 to 10 weight percent ammonium bifluoride. Both ends can be electroplated with a plating material that includes nickel. The plated ends can be positioned in alignment with the stainless steel wire and are soldered into position.
Another embodiment of the present invention is found in a method of increasing the radiopacity of a medical device that has an oxidizable substrate. The substrate can be cleaned with a cleaning and etching solution and can be activated with an aqueous solution that includes about 10 to 40 weight percent of ammonium bifluoride and can subsequently be rinsed with an aqueous solution that includes about 1 to 10 weight percent ammonium bifluoride. The activated and rinsed substrate can be electroplated with a radiopaque material.
The invention is directed to plating oxidizable materials that subsequently can be soldered using conventional solders and fluxes. Medical devices can be assembled by soldering together plated materials. Oxidizable materials can be plated with radiopaque materials to yield medical deviecs that are more visible to fluoroscopy.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value, i.e. having the same function or result. In many instances, the term “about” can include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
As used in this specification and the appended claims, any reference to “percent” or “%” are intended to be defined as weight percent, unless explicitly described to the contrary.
The following description should be read with reference to the illustrative but non-limiting drawings wherein like reference numerals indicate like elements throughout the several views.
In particular,
In the activation step 10, the substrate is contacted by the activation solution for a period of time sufficient to remove most if not all of the oxidation. The amount of time necessary can vary, depending on the ammonium bifluoride concentration of the activation solution. In some embodiments, the activation step 10 can include contacting the substrate with the activation solution for a period of time that is in the range of about 1 minute to about 30 minutes or for example, about 5 minutes.
Without wishing to be bound or limited by theory, it is believed that activation step 10 results in a substrate that is largely free of oxidation by reducing any oxidized metal back to its native form. If for example the substrate is a nickel-titanium alloy such as nitinol, the activation step 10 is believed to reduce most if not all of the TiO2 back to elemental titanium.
The activation step 10 can be followed by a rinse step 12. In some embodiments, the rinse step 12 can include submerging, dipping, spraying or otherwise contacting the substrate with a rinse solution. The rinse solution can be a dilute aqueous solution of ammonium bifluoride. In some embodiments, the rinse solution can contain in the range of about 1 to 10 weight percent ammonium bifluoride dissolved in water. In some embodiments, the rinse solution can contain about 5 weight percent ammonium bifluoride dissolved in DI water.
In the rinse step 12, the substrate is contacted with the rinse solution for a period of time sufficient to remove excess ammonium bifluoride from the substrate. The amount of time can vary, depending on the ammonium bifluoride concentration on the surface of the substrate as well as that of the rinse solution. It is recognized that as activated substrates (from activation step 10) undergo the rinse step 12, the ammonium bifluoride concentration within the rinse solution will increase. In some embodiments, the rinse step 12 can include contacting the substrate with the rinse solution for a period of time that is in the range of about 1 minute or less, for example about 30 seconds.
Without wishing to be bound or limited by theory, it is believed that the rinse step 12 removes excess ammonium bifluoride from the surface of the substrate yet leaves sufficient ammonium bifluoride to provide temporary protection against oxidation. As a result, the activated and rinsed substrate can be moved to a plating step 14 without requiring an oxygen-free environment. Of course, an inert atmosphere such as a nitrogen atmosphere could be employed, but such is neither necessary nor warranted.
Once the substrate has undergone the activation step 10 and the rinse step 12, the substrate progresses to the plating step 14. The plating step 14 can include any conventional plating process, such as electroplating or reverse current electroplating, or any known deposition process such as vapor deposition, reactive spottering, ion implantation and others.
In some embodiments, the plating step 14 involves an electroplating process. Electroplating is well known in the art and thus a detailed description thereof is not necessary herein. In some embodiments, a reverse current electroplating process can be used. It is believed that using a reverse current electroplating process can retard or even reverse any slight oxidation that may occur between the rinse step 12 and the plating step 14.
The substrate can be plated with a variety of different materials, depending on the processing requirements of subsequent manufacturing steps and the end use of the medical device that includes or contains the substrate. In some embodiments, the substrate once plated will be soldered, and it can be advantageous to provide a plating material that will be compatible with or complementary to whichever solder and flux are used.
In some embodiments, the plating material includes nickel and tin. The plating material can include tin in the range of about 60 to 70 weight percent of the plating and can include nickel in the range of about 30 to 40 weight percent of the plating. In some embodiments, the plating can include about 65 weight percent tin and about 35 weight percent nickel. The electroplating bath can include tin and nickel in amounts sufficient to achieve these plating compositions.
In some embodiments, the substrate will not be soldered. Instead, the substrate can be plated with a material that will increase the radiopacity of the substrate. In these embodiments, the substrate can be plated with a radiopaque material such as gold. The electroplating batch can include gold or other appropriate radiopaque materials in amounts sufficient to achieve an adequate coating.
In some embodiments, the electroplating bath will include amounts of ammonium bifluoride to aid in retarding or reversing any minor oxidation that occurs between the rinse step 12 and the plating step 14. The bath can also include stannose fluoborate, ammonium bifluoride and nickel sulfate.
An electroplating process can be defined in part by the power levels and time used in electroplating a substrate. In some embodiments, the plating step 14 can include plating at a current that is in the range of about 150 mA and about 200 mA for a period of about 15 to about 30 minutes, for example 22 minutes and 175 mA. Time and current may vary depending on amount of parts loaded. If more parts are loaded, increase time or current accordingly should be increased.
Activation and plating methods in accordance with various embodiments of the invention can involved additional steps prior to the activation step 10. For example, in some embodiments, the substrate can be cleaned or can be cleaned and etched prior to activation. A cleaning and etching solution can include any suitable chemicals that are intended to prepare the substrate for activation. In some embodiments, the cleaning and etching solution can include sulfamic acid and hydrogen peroxide.
A cleaning or cleaning and etching step can include submerging or otherwise contacting the substrate with the cleaning or cleaning and etching solution for a sufficient period of time to prepare the substrate for activation. In some embodiments, the substrate can be submerged or otherwise contacted with the cleaning or cleaning and etching solution for a period of time in the range of about less than one minute to about ten minutes. In some embodiments, the cleaning or cleaning and etching process can include ultrasonic cleaning, for approximately 5 minutes, for example.
In some embodiments, a cleaning or cleaning and etching step can be followed by a water rinse. In some embodiments, the plating step 14 can be followed by a water rinse, with or without ultrasonic agitation.
The methods described herein are applicable to a number of different medical devices.
In some embodiments, the plating layer 20 represents a solderable material and the substrate 18 generically represents a medical device or portion thereof that can be soldered to another medical device or portion thereof. In particular, the substrate 18 can be formed from or include a portion thereof that is formed from an oxidizable metal.
In some embodiments, the substrate 18 can be formed from a nickel-titanium alloy such as nitinol, stainless steel, gold, tantalum, titanium, beta titanium and metal alloys such as nickel-titanium alloy, nickel-chromium alloy, nickel-chromium-iron alloy, cobalt alloy, or other suitable material. In some embodiments, the substrate 18 can be a relatively stiff metal such as 304 v stainless steel or 316L stainless steel.
In some embodiments, the substrate 18 can be nitinol. The word nitinol was coined by a group of researchers at the United States Naval Ordinance Laboratory (NOL) who were the first to observe the shape memory behavior of this material. The word nitinol is an acronym including the chemical symbol for nickel (Ni), the chemical symbol for titanium (Ti), and an acronym identifying the Naval Ordinance Laboratory (NOL).
Once the substrate 18 has been plated to form the plated substrate 16, it can if desired be soldered to another material. The plated substrate 16 can be soldered to a solderable material that has not been plated, or if desired the plated substrate 16 can be soldered to another oxidizable material that has been plated in accordance with the invention.
As noted,
The wire ends 34 and 36 can be positioned in conjunction with a support wire 38. The support wire 38 can be formed from a variety of suitable materials. In some embodiments, the support wire 38 can be formed of stainless steel. The wire ends 34 and 36 can be positioned such that both are substantially parallel to the support wire 38.
In the illustrated embodiment, the wire end 34 is arranged in parallel to the support wire 38 while the wire end 36 is coiled around the support wire 38 and the wire end 34. In some embodiments, both end wires 34 and 36 can be positioned parallel to the support wire 38 and a separate wire or coil (not illustrate) could be coiled around the support wire 38 and the wire ends 34 and 36 to lend strength.
Once the support loop 30 has been positioned proximate the support wire 38, the wire ends 34 and 36 can be soldered to the support wire 38. As described above, any suitable solder such as a tin-nickel solder can be used. The soldered filter support structure 40 after soldering is illustrated for example in FIG. 5.
In
Guidewires represent another beneficial use for the plating methods of the invention.
In other embodiments, the proximal section 48 can have a constant diameter, or alternatively can have more than one taper portion (not illustrated). The distal tip 5 as shown has two constant diameter portions 60 and 62 that are interrupted by a taper portion 64. This is merely an illustrative grind profile, as the distal tip 50 could include only a taper portion without any constant diameter portions, or it could include multiple taper portions.
Each of the proximal section 48 and the distal tip 50 can be formed from a variety of metallic materials. In some embodiments, one of the proximal section 48 and the distal tip 50 can be formed of nitinol while the other is formed of stainless steel. In some embodiments, the proximal section 48 is formed of nitinol having a first set of properties while the distal tip 50 is formed of nitinol having a second set of properties.
Intravascular filters such as vena cava filters represent another application of the invention.
The apical head 78 can be formed of any suitable material, such as a metal or metal alloy. The struts 80 can may be formed from a metal or metal alloy such as titanium, platinum, tantalum, tungsten, stainless steel (e.g. type 304 or 316) or cobalt-chrome. In some embodiments, the struts 80 are formed of titanium, which is highly oxidizable. In some embodiments, the struts 80 can be formed from nitinol.
In some embodiments, the distal ends 82 of each strut 80 can undergo the activation, rinse and plating steps described herein prior to being soldered to the apical head 78. Depending on the identity of the material used to form the apical head 78, it can be beneficial to also activate, rinse and plate the apical head 78 prior to attaching the struts 80.
Number | Name | Date | Kind |
---|---|---|---|
3472230 | Fogarty | Oct 1969 | A |
3562013 | Mickelson et al. | Feb 1971 | A |
3841905 | Dixon, III | Oct 1974 | A |
3868620 | McBride et al. | Feb 1975 | A |
3926699 | Dixon | Dec 1975 | A |
3952747 | Kimmell, Jr. | Apr 1976 | A |
3990982 | Dixon | Nov 1976 | A |
3996938 | Clark, III | Dec 1976 | A |
RE29181 | Dixon, III | Apr 1977 | E |
4029556 | Monaco et al. | Jun 1977 | A |
4046150 | Schwartz et al. | Sep 1977 | A |
4297257 | Elias et al. | Oct 1981 | A |
4314876 | Kremer et al. | Feb 1982 | A |
4410396 | Somers et al. | Oct 1983 | A |
4416739 | Turner | Nov 1983 | A |
4425908 | Simon | Jan 1984 | A |
4525250 | Fahrmbacher-Lutz et al. | Jun 1985 | A |
4590938 | Segura et al. | May 1986 | A |
4591088 | Mulliner et al. | May 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4650466 | Luther | Mar 1987 | A |
4673521 | Sullivan et al. | Jun 1987 | A |
4706671 | Weinrib | Nov 1987 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4790812 | Hawkins, Jr. et al. | Dec 1988 | A |
4790813 | Kensey | Dec 1988 | A |
4790902 | Wada et al. | Dec 1988 | A |
4794928 | Kletschka | Jan 1989 | A |
4807626 | McGirr | Feb 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4921478 | Solano et al. | May 1990 | A |
4921484 | Hillstead | May 1990 | A |
4926858 | Gifford, III et al. | May 1990 | A |
4938850 | Rothschild et al. | Jul 1990 | A |
4944851 | Cordani et al. | Jul 1990 | A |
4963233 | Mathew | Oct 1990 | A |
4969891 | Gewertz | Nov 1990 | A |
4998539 | Delsanti | Mar 1991 | A |
5002560 | Machold et al. | Mar 1991 | A |
5011488 | Ginsburg | Apr 1991 | A |
5022935 | Fisher | Jun 1991 | A |
5053008 | Bajaj | Oct 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5100423 | Fearnot | Mar 1992 | A |
5100500 | Dastolfo et al. | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5109593 | Benz et al. | May 1992 | A |
5133733 | Rasmussen et al. | Jul 1992 | A |
5134040 | Benz et al. | Jul 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5152777 | Goldberg et al. | Oct 1992 | A |
5160342 | Reger et al. | Nov 1992 | A |
5211775 | Fisher et al. | May 1993 | A |
5224953 | Morgentaler | Jul 1993 | A |
5242759 | Hall | Sep 1993 | A |
5329942 | Gunther et al. | Jul 1994 | A |
5330484 | Gunther | Jul 1994 | A |
5354310 | Garnie et al. | Oct 1994 | A |
5354623 | Hall | Oct 1994 | A |
5376100 | Lefebvre | Dec 1994 | A |
5421832 | Lefebvre | Jun 1995 | A |
5423742 | Theron | Jun 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
4842579 | Shiber | Oct 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5462529 | Simpson et al. | Oct 1995 | A |
5464524 | Ogiwara et al. | Nov 1995 | A |
5536242 | Willard et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5658296 | Bates et al. | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5720764 | Naderlinger | Feb 1998 | A |
5728066 | Daneshvar | Mar 1998 | A |
5749848 | Jang et al. | May 1998 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5779716 | Cano et al. | Jul 1998 | A |
5792157 | Mische et al. | Aug 1998 | A |
5795322 | Boudewijn | Aug 1998 | A |
5800457 | Gelbfish | Sep 1998 | A |
5800509 | Boneau | Sep 1998 | A |
5800525 | Bachinski et al. | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5827324 | Cassell et al. | Oct 1998 | A |
5833644 | Zadno-Azizi et al. | Nov 1998 | A |
5833650 | Imran | Nov 1998 | A |
5846260 | Maahs | Dec 1998 | A |
5848964 | Samuels | Dec 1998 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5882193 | Wool | Mar 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5897567 | Ressemann et al. | Apr 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5919126 | Armini | Jul 1999 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5925060 | Forber | Jul 1999 | A |
5925062 | Purdy | Jul 1999 | A |
5935139 | Bates | Aug 1999 | A |
5941869 | Patterson et al. | Aug 1999 | A |
5941896 | Kerr | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5954745 | Gertler et al. | Sep 1999 | A |
5980555 | Barbut et al. | Nov 1999 | A |
5989281 | Barbut et al. | Nov 1999 | A |
5993469 | McKenzie et al. | Nov 1999 | A |
5997557 | Barbut et al. | Dec 1999 | A |
6001118 | Daniel et al. | Dec 1999 | A |
6007557 | Ambrisco et al. | Dec 1999 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6013085 | Howard | Jan 2000 | A |
6027520 | Tsugita et al. | Feb 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6051014 | Jang | Apr 2000 | A |
6051015 | Maahs | Apr 2000 | A |
6053932 | Daniel et al. | Apr 2000 | A |
6059814 | Ladd | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6068645 | Tu | May 2000 | A |
6086605 | Barbut et al. | Jul 2000 | A |
6117154 | Barbut et al. | Sep 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6136016 | Barbut et al. | Oct 2000 | A |
6142987 | Tsugita | Nov 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6171327 | Daniel et al. | Jan 2001 | B1 |
6171328 | Addis | Jan 2001 | B1 |
6179851 | Barbut et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6206868 | Parodi | Mar 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6224620 | Maahs | May 2001 | B1 |
6231544 | Tsugita et al. | May 2001 | B1 |
6235044 | Root et al. | May 2001 | B1 |
6235045 | Barbut et al. | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6245088 | Lowery | Jun 2001 | B1 |
6245089 | Daniel et al. | Jun 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6264672 | Fisher | Jul 2001 | B1 |
6267650 | Hembree | Jul 2001 | B1 |
6270513 | Tsugita et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6280413 | Clark et al. | Aug 2001 | B1 |
6287321 | Jang | Sep 2001 | B1 |
6290710 | Cryer et al. | Sep 2001 | B1 |
6309399 | Barbut et al. | Oct 2001 | B1 |
6319268 | Ambrisco et al. | Nov 2001 | B1 |
6339047 | Christopherson et al. | Jan 2002 | B1 |
6344049 | Levinson et al. | Feb 2002 | B1 |
6416386 | Hembree | Jul 2002 | B2 |
6416387 | Hembree | Jul 2002 | B2 |
6416388 | Hembree | Jul 2002 | B2 |
6416395 | Hembree | Jul 2002 | B1 |
6416397 | Hembree | Jul 2002 | B2 |
6416398 | Hembree | Jul 2002 | B2 |
6416399 | Hembree | Jul 2002 | B2 |
6419550 | Hembree | Jul 2002 | B2 |
6422919 | Hembree | Jul 2002 | B2 |
6422923 | Hembree | Jul 2002 | B2 |
6431952 | Hembree | Aug 2002 | B2 |
6447664 | Taskovics et al. | Sep 2002 | B1 |
20010044262 | Hembree | Nov 2001 | A1 |
20010046832 | Hembree | Nov 2001 | A1 |
Number | Date | Country |
---|---|---|
28 21 048 | Jul 1980 | DE |
34 17 738 | Nov 1985 | DE |
40 30 998 | Oct 1990 | DE |
199 16 162 | Oct 2000 | DE |
0 200 688 | Nov 1986 | EP |
0 293 605 | Dec 1988 | EP |
0 411 118 | Feb 1991 | EP |
0 427 429 | May 1991 | EP |
0 437 121 | Jul 1991 | EP |
449646 | Oct 1991 | EP |
0 472 334 | Feb 1992 | EP |
0 472 368 | Feb 1992 | EP |
0 533 511 | Mar 1993 | EP |
0 655 228 | Nov 1994 | EP |
0 686 379 | Jun 1995 | EP |
0 696 447 | Feb 1996 | EP |
0 737 450 | Oct 1996 | EP |
0 743 046 | Nov 1996 | EP |
0 759 287 | Feb 1997 | EP |
0 771 549 | May 1997 | EP |
0 784 988 | Jul 1997 | EP |
0 852 132 | Jul 1998 | EP |
0 934 729 | Aug 1999 | EP |
1 127 556 | Aug 2001 | EP |
2 580 504 | Oct 1986 | FR |
2 643 250 | Aug 1990 | FR |
2 666 980 | Mar 1992 | FR |
2 694 687 | Aug 1992 | FR |
2 768 326 | Mar 1999 | FR |
2 020 557 | Jan 1983 | GB |
6 116 782 | Apr 1994 | JP |
8-187294 | Jul 1996 | JP |
08218185 | Aug 1996 | JP |
764684 | Sep 1980 | SU |
WO 8809683 | Dec 1988 | WO |
WO 9203097 | Mar 1992 | WO |
WO 9414389 | Jul 1994 | WO |
WO 9424946 | Nov 1994 | WO |
WO 9601591 | Jan 1996 | WO |
WO 9610375 | Apr 1996 | WO |
WO 9619941 | Jul 1996 | WO |
WO 9623441 | Aug 1996 | WO |
WO 9633677 | Oct 1996 | WO |
WO 9717100 | May 1997 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9742879 | Nov 1997 | WO |
WO 9802084 | Jan 1998 | WO |
WO 9802112 | Jan 1998 | WO |
WO 9823322 | Jun 1998 | WO |
WO 9833443 | Aug 1998 | WO |
WO 9834673 | Aug 1998 | WO |
WO 9836786 | Aug 1998 | WO |
WO 9838920 | Sep 1998 | WO |
WO 9838929 | Sep 1998 | WO |
WO 9839046 | Sep 1998 | WO |
WO 9839053 | Sep 1998 | WO |
WO 9846297 | Oct 1998 | WO |
WO 9847447 | Oct 1998 | WO |
WO 9849952 | Nov 1998 | WO |
WO 9850103 | Nov 1998 | WO |
WO 9851237 | Nov 1998 | WO |
WO 9855175 | Dec 1998 | WO |
WO 9909895 | Mar 1999 | WO |
WO 9922673 | May 1999 | WO |
WO 9923976 | May 1999 | WO |
WO 9925252 | May 1999 | WO |
WO 9930766 | Jun 1999 | WO |
WO 9940964 | Aug 1999 | WO |
WO 9942059 | Aug 1999 | WO |
WO 9944510 | Sep 1999 | WO |
WO 9944542 | Sep 1999 | WO |
WO 9955236 | Nov 1999 | WO |
WO 9958068 | Nov 1999 | WO |
WO 0007521 | Feb 2000 | WO |
WO 0007655 | Feb 2000 | WO |
WO 0009054 | Feb 2000 | WO |
WO 0016705 | Mar 2000 | WO |
WO 0049970 | Aug 2000 | WO |
WO 0053120 | Sep 2000 | WO |
WO 0067664 | Nov 2000 | WO |
WO 0067665 | Nov 2000 | WO |
WO 0067666 | Nov 2000 | WO |
WO 0067668 | Nov 2000 | WO |
WO 0067669 | Nov 2000 | WO |
WO 0105462 | Jan 2001 | WO |
WO 0108595 | Feb 2001 | WO |
WO 0108596 | Feb 2001 | WO |
WO 0108742 | Feb 2001 | WO |
WO 0108743 | Feb 2001 | WO |
WO 0110320 | Feb 2001 | WO |
WO 0115629 | Mar 2001 | WO |
WO 0121077 | Mar 2001 | WO |
WO 0121100 | Mar 2001 | WO |
WO 0126726 | Apr 2001 | WO |
WO 0135857 | May 2001 | WO |
WO 0143662 | Jun 2001 | WO |
WO 0147579 | Jul 2001 | WO |
WO 0149208 | Jul 2001 | WO |
WO 0149209 | Jul 2001 | WO |
WO 0149215 | Jul 2001 | WO |
WO 0149355 | Jul 2001 | WO |
WO 0152768 | Jul 2001 | WO |
WO 0158382 | Aug 2001 | WO |
WO 0160442 | Aug 2001 | WO |
WO 0167989 | Sep 2001 | WO |
WO 0170326 | Sep 2001 | WO |
WO 0172205 | Oct 2001 | WO |
WO 0187183 | Nov 2001 | WO |
WO 0189413 | Nov 2001 | WO |
WO 0191824 | Dec 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20040188261 A1 | Sep 2004 | US |